Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Read more
NEWS & MEDIA
Read our recent announcements
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
All
Press
Publications
Presentations
Publication
July 24, 2024
Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery
Read more
Press
Announcement
June 18, 2024
How two academic chemists turned San Diego startup Iambic into an AI force
Read more
Press
Announcement
June 18, 2024
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
Read more
Press
Announcement
June 17, 2024
Iambic and NVIDIA: Using AI to chart a faster course for drug discovery
Read more
Publication
June 1, 2024
IAM1363-01: A Phase 1/1b Study of a Selective and Brain-Penetrant HER2 Inhibitor for HER2-Driven Solid Tumors
Read more
Press
Presentation
Announcement
May 23, 2024
Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
Read more
Press
Announcement
April 8, 2024
Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform
Read more
Publication
April 8, 2024
Validation of a Novel Type II HER2 Inhibitor Through Preclinical Studies Across Various Cancer Models (AACR 2024 Poster)
Read more
Press
Announcement
April 5, 2024
Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
Read more
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
Iambic Announces Pricing of Initial Public Offering
Press
October 14, 2026
Iambic Announces Pricing of Initial Public Offering
Read more
Press
October 5, 2026
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Read more
Press
September 21, 2026
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Read more
Press
September 21, 2026
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
Read more
Press
June 22, 2026
Bayer and Iambic collaborate to advance drug discovery with AI
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Publication
December 7, 2025
Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery
Read more
Publication
December 3, 2025
San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 19, 2025
A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)
Read more
Publication
September 9, 2025
IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Read more
Publication
May 5, 2025
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Read more
Publication
April 29, 2025
A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)
Read more
Publication
December 16, 2024
NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 29, 2024
Enchant whitepaper: Breaking the data wall between lab and clinic
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Presentation
January 13, 2026
JPM Healthcare Conference 2026 Company Presentation
Read more
Presentation
October 30, 2025
Promise & Reality: Decoding AI’s Impact On Drug Development
Read more
Presentation
October 28, 2025
From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Read more
Presentation
September 23, 2025
Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development
Read more
Presentation
September 22, 2025
Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance
Read more
Presentation
September 10, 2025
Predictive Drug Discovery with Enchant v2
Read more
Presentation
August 18, 2025
Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25
Read more
Presentation
August 11, 2025
Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum
Read more
For media requests
Contact our communications team at media@iambic.ai
Contact us
Better technology for better medicines
GET IN TOUCH
contact@iambic.ai
(619) 330-5499
COMPANY
AboutNews & MediaCareersContactInvestors
TECHNOLOGY
PlatformPipelinePartners
Privacy Policy
Terms of Use
Copyright © 2026 Iambic Therapeutics, Inc. All Rights Reserved.